WO2012174013A3 - Treatment of cardiovascular disease, stroke, and inflammatory conditions - Google Patents

Treatment of cardiovascular disease, stroke, and inflammatory conditions Download PDF

Info

Publication number
WO2012174013A3
WO2012174013A3 PCT/US2012/042092 US2012042092W WO2012174013A3 WO 2012174013 A3 WO2012174013 A3 WO 2012174013A3 US 2012042092 W US2012042092 W US 2012042092W WO 2012174013 A3 WO2012174013 A3 WO 2012174013A3
Authority
WO
WIPO (PCT)
Prior art keywords
stroke
treatment
cardiovascular disease
inflammatory conditions
conditions
Prior art date
Application number
PCT/US2012/042092
Other languages
French (fr)
Other versions
WO2012174013A2 (en
Inventor
Karen J. Brunke
Toshio Uemura
Fujiko Takamura
Original Assignee
Cardeus Pharmaceuticals, Inc.
Astellas Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardeus Pharmaceuticals, Inc., Astellas Pharma, Inc. filed Critical Cardeus Pharmaceuticals, Inc.
Publication of WO2012174013A2 publication Critical patent/WO2012174013A2/en
Publication of WO2012174013A3 publication Critical patent/WO2012174013A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reversible P2Y12 receptor antagonists are administered for the treatment of cardiovascular disease, stroke, and other inflammatory diseases and conditions.
PCT/US2012/042092 2011-06-14 2012-06-12 Treatment of cardiovascular disease, stroke, and inflammatory conditions WO2012174013A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496905P 2011-06-14 2011-06-14
US61/496,905 2011-06-14

Publications (2)

Publication Number Publication Date
WO2012174013A2 WO2012174013A2 (en) 2012-12-20
WO2012174013A3 true WO2012174013A3 (en) 2013-04-04

Family

ID=47357692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/042092 WO2012174013A2 (en) 2011-06-14 2012-06-12 Treatment of cardiovascular disease, stroke, and inflammatory conditions

Country Status (1)

Country Link
WO (1) WO2012174013A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080045494A1 (en) * 2006-07-04 2008-02-21 Astrazeneca Ab Pyridine Analogues VI
US7488739B2 (en) * 2003-07-24 2009-02-10 Astellas Pharma Inc. Quinolone derivative or salt thereof
US20090197834A1 (en) * 2006-03-16 2009-08-06 Astellas Pharma Inc. Quinolone derivative or pharmaceutically acceptable salt thereof
US20100113391A1 (en) * 2007-04-19 2010-05-06 Astellas Pharma Inc. Bicyclic heterocyclic compound
US20100210654A1 (en) * 2007-03-08 2010-08-19 Rheinische Friedrich-Wilhelms Universität Bonn Novel p2y12 receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488739B2 (en) * 2003-07-24 2009-02-10 Astellas Pharma Inc. Quinolone derivative or salt thereof
US20090197834A1 (en) * 2006-03-16 2009-08-06 Astellas Pharma Inc. Quinolone derivative or pharmaceutically acceptable salt thereof
US20080045494A1 (en) * 2006-07-04 2008-02-21 Astrazeneca Ab Pyridine Analogues VI
US20100210654A1 (en) * 2007-03-08 2010-08-19 Rheinische Friedrich-Wilhelms Universität Bonn Novel p2y12 receptor antagonists
US20100113391A1 (en) * 2007-04-19 2010-05-06 Astellas Pharma Inc. Bicyclic heterocyclic compound

Also Published As

Publication number Publication date
WO2012174013A2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
LTC2785706I2 (en) SUBSTITUTED 4-PHENYL-PYRIDINES FOR THE TREATMENT OF NK-RECEPTOR-RELATED DISEASES
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
IL238868A0 (en) Compositions and methods for treating neoplasia, inflammatory disease and other disorders
CL2013003333A1 (en) Compounds derived from pregnenolone, cb1 receptor antagonists; Pharmaceutical composition: and its use for the treatment of bladder and gastrointestinal disorders, inflammatory diseases, cardiovascular diseases, among others.
CO6940374A2 (en) Compositions, uses and methods for the treatment of disorders and metabolic diseases
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
WO2010151640A3 (en) Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
WO2013012915A9 (en) Heterocyclic compounds and uses thereof
DK2539015T3 (en) retinal lESION
WO2011017108A3 (en) Cyclopropyl modulators of p2y12 receptor
WO2012125438A8 (en) Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
WO2013106273A3 (en) Peptides and methods of using same
WO2013007596A3 (en) Oral treatment of inflammatory bowel disease
WO2012125981A3 (en) Raf kinase inhibitors
WO2013023059A3 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
IL233238A (en) Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application
CL2013001445A1 (en) Compounds derived from diphenylamine; Pharmaceutical composition and use in the treatment of inflammatory diseases, such as cancer.
IT1405996B1 (en) PROCEDURE FOR THE PREPARATION OF 2,5-DIAMINOTOLUOL
ITTO20110857A1 (en) PROCEDURE FOR THE PRODUCTION OF CYCLOHEXANONOSSIN.
WO2012174013A3 (en) Treatment of cardiovascular disease, stroke, and inflammatory conditions
IT1401895B1 (en) NATURAL PHARMACOLOGICAL PRESIDIUM FOR THE PREVENTION OF INFLAMMATORY DISEASES OF PARODONTO.
EP2701702A4 (en) Oxymetazoline for the treatment of ano-rectal disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12801138

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014515921

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12801138

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: JP